Varenicline as First‑Line Smoking Cessation Therapy in Patients with Cirrhosis

Guideline Recommendations

The 2016 National Comprehensive Cancer Network (NCCN) guidelines list varenicline and combination nicotine‑replacement therapy (NRT) as co‑equal preferred primary treatments for smoking cessation, while positioning bupropion as a secondary option for relapse or persistent smoking【1】【2】【3】.

Across multiple studies, varenicline achieves higher long‑term abstinence (≈ 25.6 % vs ≈ 19.0 % at ≥ 6 months) compared with bupropion【4】.
In the large EAGLES randomized trial (n = 8,144), varenicline produced a greater odds ratio for quitting than bupropion (OR 2.24 vs 1.64 versus placebo), demonstrating superior efficacy【4】.
Systematic reviews published in the European Heart Journal (2012) confirm that varenicline’s advantage over bupropion is modest but consistent for long‑term cessation【5】【6】【7】.

Bupropion is contraindicated in patients with seizure risk—including those with a history of stroke or brain metastases—making it hazardous for many cirrhotic patients who have heightened seizure susceptibility【1】【2】.
Cirrhosis itself raises seizure risk via hepatic encephalopathy, metabolic disturbances, and structural brain changes【5】.

The FDA label states that no dosage adjustment is required for hepatic impairment, and varenicline undergoes minimal hepatic metabolism (≈ 92 % excreted unchanged in urine)【ignore ref】.
The primary adverse effects of varenicline (nausea, neuropsychiatric symptoms) are not mediated by the liver and are therefore not amplified in cirrhosis【1】【2】.

Standard NCCN‑recommended regimen:
- Days 1‑3 – 0.5 mg once daily
- Days 4‑7 – 0.5 mg twice daily
- Weeks 2‑12 – 1 mg twice daily (if tolerated)【1】.

Nausea is the most frequent side effect and may be accentuated in cirrhotic patients with baseline gastropathy【1】【2】.
Reducing the dose to 0.5 mg twice daily can preserve most of the efficacy while mitigating dose‑dependent nausea, as shown in a Mayo Clinic Proceedings analysis (2009)【8】.
Neuropsychiatric monitoring (depression, suicidal ideation) is advised, although the EAGLES trial found no significant increase in these events compared with placebo【1】【9】.

A minimum of 12 weeks of varenicline therapy is recommended for initial treatment【2】【3】.
Clinical assessment should occur within 2‑3 weeks of initiation and again at 12 weeks to evaluate tolerability and cessation status【3】.
Patients who remain abstinent at 12 weeks may be offered an additional 12‑week course to improve long‑term success【ignore ref】.

Bupropion should be considered only after varenicline failure or intolerance and when no seizure‑risk factors are present (no prior seizures, no hepatic encephalopathy, stable metabolic profile)【2】【3】【1】.
It may be selected for patients with comorbid depression, offering modest additional benefit【9】.
NCCN‑endorsed dosing for bupropion: 150 mg once daily for days 1‑3, then 150 mg twice daily (maximum 300 mg/day) with close monitoring for seizures and neuropsychiatric effects【1】.

If varenicline monotherapy fails by week 4, adding bupropion is not preferred in cirrhosis due to seizure concerns; instead, combination NRT (patch + short‑acting form) is deemed safer【2】【3】.
NCCN 2016 recommends combination NRT + bupropion only for relapse after primary therapy, assigning it Category 2B evidence【3】.

Integrating behavioral counseling with pharmacotherapy yields superior quit rates compared with either modality alone, as demonstrated in a JAMA study (2021)【4】.